Exelixis TKI trims death risk 20% — Phase 3 readout

Exelixis reported Phase 3 data showing its oral TKI zanzalintinib combined with Roche’s Tecentriq reduced the risk of death by 20% versus the Stivarga comparator in previously treated metastatic colorectal cancer. The company presented the readout at ESMO and highlighted a median overall survival improvement in the intent-to-treat population. Safety showed higher grade 3–4 events with the zanzalintinib combo versus the comparator, consistent with TKI–checkpoint inhibitor combinations reported previously.